Sarepta Therapeutics
The Principal Engineer will lead process development, scale‑up, technology transfer, and external manufacturing oversight for Sarepta’s antibody‑oligonucleotide conjugate (AOC) and adeno‑associated virus (AAV) drug substance programs. The role provides technical leadership across internal and CDMO/CMO activities, ensuring process robustness, product quality, GMP readiness, and supporting CMC regulatory deliverables.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Sarepta Therapeutics.
23% above the average for this role
Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade
2 weeks ago
CMC Professional
Crescent Biopharma
Scientist-II
Integrated Resources INC
Senior Associate Scientist, Viral Delivery Technologies (AAV)
Regeneron Pharmaceuticals
Scientific Director, Bioconjugation Development
lifelancer
Associate Director Antibody Development United States
alnylam
Advisor, Downstream Process Development – Viral Vectors
Eli Lilly and Company